|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
|
US5433081A
(en)
*
|
1993-01-22 |
1995-07-18 |
Major; Thomas O. |
Refrigerant recovery and purification method and apparatus with oil adsorbent separator
|
|
AU679566B2
(en)
|
1993-09-03 |
1997-07-03 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
|
US5502177A
(en)
*
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
JP4053595B2
(ja)
*
|
1995-09-22 |
2008-02-27 |
メディカル・リサーチ・カウンシル |
核酸の突然変異誘発におけるまたはそれに関する改良
|
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
|
US20040033973A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Muthiah Manoharan |
Compounds and oligomeric compounds comprising novel nucleobases
|
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
US6617422B1
(en)
*
|
1997-05-23 |
2003-09-09 |
Peter Nielsen |
Peptide nucleic acid monomers and oligomers
|
|
JP2002510319A
(ja)
|
1997-07-01 |
2002-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6007992A
(en)
*
|
1997-11-10 |
1999-12-28 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US6028183A
(en)
*
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
|
ATE284407T1
(de)
*
|
1997-11-07 |
2004-12-15 |
Isis Pharmaceuticals Inc |
Pyrimidinderivate als markierte bindungspartner
|
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
|
AU753270B2
(en)
*
|
1998-05-21 |
2002-10-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
|
EP1080103A4
(de)
*
|
1998-05-21 |
2003-07-02 |
Isis Pharmaceuticals Inc |
Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
|
|
EP1093373A4
(de)
*
|
1998-07-02 |
2005-04-13 |
Univ Columbia |
OLIGONUKLEOTIDE INHIBITOREN DES bcl-xl
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
|
US20040081959A9
(en)
*
|
1999-12-08 |
2004-04-29 |
Epoch Biosciences, Inc. |
Fluorescent quenching detection reagents and methods
|
|
US6727356B1
(en)
|
1999-12-08 |
2004-04-27 |
Epoch Pharmaceuticals, Inc. |
Fluorescent quenching detection reagents and methods
|
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
|
US6323009B1
(en)
*
|
2000-06-28 |
2001-11-27 |
Molecular Staging, Inc. |
Multiply-primed amplification of nucleic acid sequences
|
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
CA2425779C
(en)
|
2000-10-12 |
2013-08-06 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7718354B2
(en)
*
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
|
US20040121311A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in livestock
|
|
US20030027135A1
(en)
*
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
|
US7666588B2
(en)
*
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
|
US20040121314A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in containers
|
|
US20040121310A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in forensic studies
|
|
JP2004533815A
(ja)
|
2001-03-14 |
2004-11-11 |
ミリアド・ジェネティックス・インコーポレイテッド |
Tsg101−gag相互作用およびその使用
|
|
KR100628425B1
(ko)
|
2001-06-20 |
2006-09-28 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
EP2270024B1
(de)
|
2001-06-21 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
|
US7217510B2
(en)
*
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
JP2005536439A
(ja)
|
2001-09-18 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断及び治療のための組成物と方法
|
|
US7070933B2
(en)
*
|
2001-09-28 |
2006-07-04 |
Gen-Probe Incorporated |
Inversion probes
|
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
|
US7553619B2
(en)
*
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
|
US20030228571A1
(en)
*
|
2002-04-01 |
2003-12-11 |
Ecker David J. |
Method for rapid detection and identification of viral bioagents
|
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
|
WO2004013160A2
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
|
CA2499770A1
(en)
|
2002-09-20 |
2004-04-01 |
Yale University |
Riboswitches, methods for their use, and compositions for use with riboswitches.
|
|
CA2498320A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Integrated Dna Technologies, Inc. |
Anthraquinone quencher dyes, their methods of preparation and use
|
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
|
JP2006515318A
(ja)
*
|
2002-10-29 |
2006-05-25 |
ファルマシア・コーポレーション |
特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
|
|
EP1560839A4
(de)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Chimäre oligomere verbindungen und derenverwendung in der genmodulation
|
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
EP2957568B1
(de)
*
|
2002-11-05 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen mit alternierenden 2'-modifizierten nukleosiden zur verwendung bei der genmodulation
|
|
WO2004044181A2
(en)
|
2002-11-13 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
|
DK1569685T3
(da)
|
2002-11-15 |
2012-11-12 |
Univ Colorado Regents |
Komplementmodulatorer rettet mod komplementreceptor-2
|
|
WO2004046330A2
(en)
*
|
2002-11-15 |
2004-06-03 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
|
EP2410332A1
(de)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Methode zur Identifizierung von purinergen Modulatoren des Geruchssystems
|
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
EP1578399A4
(de)
|
2002-12-06 |
2007-11-28 |
Isis Pharmaceuticals Inc |
Verfahren für die rasche identifikation von pathogenen bei tier und mensch
|
|
US20040121315A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby
|
|
US20040122857A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby
|
|
US20040121312A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of the absence of bioagents
|
|
US9487823B2
(en)
*
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
|
JP4886298B2
(ja)
|
2002-12-20 |
2012-02-29 |
キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
核酸増幅
|
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
|
EP1597366B1
(de)
|
2003-02-11 |
2012-11-21 |
Antisense Therapeutics Ltd |
Modulation der expression des insulinähnlichen wachstumsfaktor i-rezeptors
|
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
US8046171B2
(en)
*
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
|
US7964343B2
(en)
*
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
|
US7276599B2
(en)
*
|
2003-06-02 |
2007-10-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
|
US7786290B2
(en)
|
2003-06-13 |
2010-08-31 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
|
US20060241072A1
(en)
*
|
2003-06-20 |
2006-10-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
|
EP1648914A4
(de)
|
2003-07-31 |
2009-12-16 |
Regulus Therapeutics Inc |
Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
SI1660057T1
(sl)
|
2003-08-27 |
2012-10-30 |
Ophthotech Corp |
Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
US20060240412A1
(en)
*
|
2003-09-11 |
2006-10-26 |
Hall Thomas A |
Compositions for use in identification of adenoviruses
|
|
US20100035239A1
(en)
*
|
2003-09-11 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of bacteria
|
|
US20080138808A1
(en)
*
|
2003-09-11 |
2008-06-12 |
Hall Thomas A |
Methods for identification of sepsis-causing bacteria
|
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
|
US8242254B2
(en)
|
2003-09-11 |
2012-08-14 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
|
PE20050469A1
(es)
|
2003-09-18 |
2005-09-10 |
Lilly Co Eli |
Modulacion de la expresion de eif4e
|
|
JP5379347B2
(ja)
*
|
2003-09-18 |
2013-12-25 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
4’−チオヌクレオシドおよびオリゴマー化合物
|
|
PL1678194T3
(pl)
|
2003-10-10 |
2014-01-31 |
Alchemia Oncology Pty Ltd |
Modulowanie syntezy i degradacji hialuronianu w leczeniu choroby
|
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
WO2005049849A2
(en)
*
|
2003-11-14 |
2005-06-02 |
Integrated Dna Technologies, Inc. |
Fluorescence quenching azo dyes, their methods of preparation and use
|
|
ATE453405T1
(de)
|
2003-11-17 |
2010-01-15 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
|
EP1711606A2
(de)
|
2004-01-20 |
2006-10-18 |
Isis Pharmaceuticals, Inc. |
Modulation der expression des glucocorticoidrezeptors
|
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
|
EP2123759B1
(de)
*
|
2004-02-06 |
2014-01-15 |
Thermo Fisher Scientific Biosciences Inc. |
Stabilisierte RNA als Transfektionskontrollen und Dämpfungsreagenzien
|
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
|
US7666592B2
(en)
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
EP2700720A3
(de)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
|
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
CA2561741C
(en)
|
2004-04-05 |
2016-09-27 |
Alnylam Pharmaceuticals, Inc. |
Processes and reagents for oligonucleotide synthesis and purification
|
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
|
EP3225633B1
(de)
|
2004-05-21 |
2020-03-25 |
The UAB Research Foundation |
Variable lymphozytenrezeptoren, verwandte polypeptide und nukleinsäuren sowie verwendung dafür
|
|
JP4810533B2
(ja)
*
|
2004-05-24 |
2011-11-09 |
アイビス バイオサイエンシズ インコーポレイティッド |
ディジタルスレショルド化による選択的イオン濾過作用を用いた質量分光測定法
|
|
US20050266411A1
(en)
*
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
CA2569419A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
EP1766052A4
(de)
*
|
2004-06-03 |
2009-12-16 |
Isis Pharmaceuticals Inc |
Chimärische oligomere zusammensetzungen mit gap
|
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
WO2006135400A2
(en)
|
2004-08-24 |
2006-12-21 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification of recombinant organisms
|
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
WO2006032143A1
(en)
|
2004-09-23 |
2006-03-30 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
|
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
|
US8084207B2
(en)
*
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
|
US8182992B2
(en)
|
2005-03-03 |
2012-05-22 |
Ibis Biosciences, Inc. |
Compositions for use in identification of adventitious viruses
|
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
|
US7476733B2
(en)
*
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
|
US8309303B2
(en)
*
|
2005-04-01 |
2012-11-13 |
Qiagen Gmbh |
Reverse transcription and amplification of RNA with simultaneous degradation of DNA
|
|
CA2601554A1
(en)
|
2005-05-20 |
2006-11-30 |
Integrated Dna Technologies, Inc. |
Compounds and methods for labeling oligonucleotides
|
|
JP5329949B2
(ja)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
|
WO2007014045A2
(en)
*
|
2005-07-21 |
2007-02-01 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification and quantitation of nucleic acid variants
|
|
DE602006017405D1
(de)
|
2005-08-11 |
2010-11-18 |
Synthetic Genomics Inc |
Verfahren zur in vitro-rekombination
|
|
KR20080036646A
(ko)
|
2005-08-17 |
2008-04-28 |
메덱시스 에스.에이. |
Ck19 발현 측정을 위한 조성물 및 방법
|
|
DE602006019455D1
(de)
|
2005-08-29 |
2011-02-17 |
Regulus Therapeutics Inc |
Verfahren für mir-122a-modulation
|
|
DE102005042073B4
(de)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Faserlaser
|
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
|
WO2007035759A1
(en)
|
2005-09-19 |
2007-03-29 |
Johnson & Johnson Pharmaceutical Research & Development L.L.C. |
Modulation of glucocorticoid receptor expression
|
|
EP2096170B1
(de)
|
2005-09-19 |
2011-08-10 |
Isis Pharmaceuticals, Inc. |
Modulation der Glucagonrezeptorexpression
|
|
CA2625891A1
(en)
*
|
2005-10-14 |
2007-04-26 |
Carlton D. Donald |
Inhibition of pax2 by defb1 induction as a therapy for cancer
|
|
US8080534B2
(en)
*
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
|
EP2325315B1
(de)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
|
|
EP2363134B1
(de)
|
2005-11-09 |
2014-01-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression von Faktor V Leiden Mutationsgen
|
|
EP1966377A2
(de)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation der eif4e-bp2-expression
|
|
US8313901B2
(en)
*
|
2005-12-21 |
2012-11-20 |
Yale University |
Methods and compositions related to the modulation of riboswitches
|
|
JP5713377B2
(ja)
|
2005-12-28 |
2015-05-07 |
ザ スクリプス リサーチ インスティテュート |
薬物標的としての天然アンチセンスおよび非コードrna転写物
|
|
EP1984381B1
(de)
|
2006-01-27 |
2010-09-29 |
Isis Pharmaceuticals, Inc. |
6-modifizierte bicyclische nukleinsäureanaloga
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
JP5213723B2
(ja)
|
2006-01-27 |
2013-06-19 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
マイクロrnaの調節に使用するためのオリゴマー化合物及び組成物
|
|
KR101362681B1
(ko)
|
2006-03-31 |
2014-02-13 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 유전자의 발현을 억제하는 조성물 및 억제 방법
|
|
WO2007125173A2
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
|
WO2007131237A2
(en)
*
|
2006-05-05 |
2007-11-15 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of ptp1b
|
|
DE102006020885A1
(de)
*
|
2006-05-05 |
2007-11-08 |
Qiagen Gmbh |
Einführung von Sequenzelementen in Nukleinsäuren
|
|
ES2389737T3
(es)
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
|
EP2023938A4
(de)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation von chrebp-expression
|
|
US20090280188A1
(en)
*
|
2006-06-23 |
2009-11-12 |
Northwestern University |
Asymmetric functionalizated nanoparticles and methods of use
|
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
|
WO2008033866A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Yale University |
Methods and compositions for the use of lysine riboswitches
|
|
WO2008143627A2
(en)
*
|
2006-09-14 |
2008-11-27 |
Ibis Biosciences, Inc. |
Targeted whole genome amplification method for identification of pathogens
|
|
US8252755B2
(en)
*
|
2006-09-22 |
2012-08-28 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
|
WO2008042156A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Northwestern University |
Maximizing oligonucleotide loading on gold nanoparticle
|
|
EP2069788B1
(de)
|
2006-10-05 |
2017-03-01 |
Massachusetts Institute of Technology |
Multifunktionelle kodierte partikel für hochdurchsatzanalysen
|
|
EP2104516B1
(de)
|
2006-11-01 |
2015-01-07 |
University of Rochester |
Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
|
|
JP2010512327A
(ja)
*
|
2006-12-11 |
2010-04-22 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
病的血管形成および脈管透過性の処置用の組成物および方法
|
|
EP2913341A1
(de)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
|
|
CA2691066C
(en)
|
2007-02-09 |
2018-07-31 |
Northwestern University |
Particles for detecting intracellular targets
|
|
JP5680304B2
(ja)
*
|
2007-02-23 |
2015-03-04 |
アイビス バイオサイエンシズ インコーポレイティッド |
迅速な法医学的dna分析法
|
|
KR20100015757A
(ko)
|
2007-03-22 |
2010-02-12 |
예일 유니버시티 |
택일적 스플라이싱을 조절하는 리보스위치와 관련된 방법 및 조성물
|
|
US20100204266A1
(en)
*
|
2007-03-23 |
2010-08-12 |
Ibis Biosciences, INC |
Compositions for use in identification of mixed populations of bioagents
|
|
CA2682161A1
(en)
|
2007-03-29 |
2008-10-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from ebola virus
|
|
CN101849020A
(zh)
*
|
2007-05-29 |
2010-09-29 |
耶鲁大学 |
核糖开关及使用核糖开关的方法和组合物
|
|
JP2010528616A
(ja)
*
|
2007-05-29 |
2010-08-26 |
イェール ユニバーシティー |
オルタナティブスプライシングとrnaのスプライシングを調節するリボスイッチに関連する方法と組成物
|
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
MX2009013046A
(es)
|
2007-05-30 |
2010-02-17 |
Univ Northwestern |
Nanoparticulas con grupo funcional de acido nucleico para aplicaciones terapeuticas.
|
|
WO2008151023A2
(en)
|
2007-06-01 |
2008-12-11 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
|
DK2173760T4
(en)
|
2007-06-08 |
2016-02-08 |
Isis Pharmaceuticals Inc |
Carbocyclic bicyclic nukleinsyreanaloge
|
|
US8278283B2
(en)
*
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
|
CN101821277B
(zh)
|
2007-08-15 |
2014-05-07 |
Isis制药公司 |
四氢吡喃核酸类似物
|
|
WO2009032693A2
(en)
*
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
|
US8445217B2
(en)
|
2007-09-20 |
2013-05-21 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
|
US7951785B2
(en)
*
|
2007-09-21 |
2011-05-31 |
California Institute Of Technology |
NFIA in glial fate determination, glioma therapy and astrocytoma treatment
|
|
WO2009060124A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
|
US8916531B2
(en)
*
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
|
EP2848688A1
(de)
|
2007-12-10 |
2015-03-18 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
|
CA2709875C
(en)
|
2008-01-02 |
2019-07-16 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
EP2265627A2
(de)
*
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexitolnukleinsäureanaloga
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
CN104975020B
(zh)
|
2008-02-11 |
2020-01-17 |
菲奥医药公司 |
经修饰的RNAi多核苷酸及其用途
|
|
JP2011518117A
(ja)
|
2008-03-05 |
2011-06-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Eg5およびVEGF遺伝子の発現を阻害するための組成物および方法
|
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
|
WO2009124238A1
(en)
*
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
EP2274423A2
(de)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
|
|
DK2281042T3
(en)
|
2008-04-18 |
2015-11-09 |
Baxter Int |
Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes
|
|
CA2722668A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Wyeth Llc |
Methods for treating inflammation
|
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
|
EP2323667A4
(de)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
|
|
MX2011002143A
(es)
|
2008-08-25 |
2011-07-20 |
Excaliard Pharmaceuticals Inc |
Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
|
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
|
EP2349549B1
(de)
|
2008-09-16 |
2012-07-18 |
Ibis Biosciences, Inc. |
Mischpatronen, mischstationen und verwandte ausrüstungen, und system
|
|
WO2010033625A1
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Microplate handling systems and related computer program products and methods
|
|
EP2347254A2
(de)
|
2008-09-16 |
2011-07-27 |
Ibis Biosciences, Inc. |
Probenverarbeitungseinheiten, -systeme und damit verbundene verfahren
|
|
US8796443B2
(en)
|
2008-09-22 |
2014-08-05 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
EP2361256B1
(de)
|
2008-09-24 |
2013-04-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenylverbindungen als nukleinsäureanaloga
|
|
WO2010036698A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
|
PL2350043T3
(pl)
|
2008-10-09 |
2014-09-30 |
Tekmira Pharmaceuticals Corp |
Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
|
|
KR101773551B1
(ko)
|
2008-10-15 |
2017-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
인자 11 발현의 조정
|
|
WO2010048228A2
(en)
|
2008-10-20 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
CN102264374B
(zh)
|
2008-10-24 |
2015-01-07 |
Isis制药公司 |
5′和2′双取代的核苷和由其制备的低聚化合物
|
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
EP2365803B1
(de)
*
|
2008-11-24 |
2017-11-01 |
Northwestern University |
Polyvalente rna-nanoteilchen-zusammensetzungen
|
|
KR101881596B1
(ko)
|
2008-12-02 |
2018-07-24 |
웨이브 라이프 사이언시스 재팬 인코포레이티드 |
인 원자 변형된 핵산의 합성 방법
|
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
|
CN102307997B
(zh)
|
2008-12-04 |
2018-03-30 |
库尔纳公司 |
通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
|
|
KR101840618B1
(ko)
|
2008-12-04 |
2018-03-20 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
WO2010071821A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Abbott Laboratories |
Diagnostic test for mutations in codons 12-13 of human k-ras
|
|
WO2010080616A1
(en)
|
2008-12-19 |
2010-07-15 |
Abbott Laboratories |
Molecular assay for diagnosis of malaria
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
KR101546673B1
(ko)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
전자 사진용 토너 및 그의 제조방법
|
|
JP2012516155A
(ja)
|
2009-01-27 |
2012-07-19 |
キアゲン ゲーザーズバーグ |
エンドポイント均一蛍光検出を用いた好熱性ヘリカーゼ依存性増幅技術
|
|
WO2010088537A2
(en)
|
2009-01-29 |
2010-08-05 |
Alnylam Pharmaceuticals, Inc. |
Improved lipid formulation
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
|
WO2010093943A1
(en)
*
|
2009-02-12 |
2010-08-19 |
Ibis Biosciences, Inc. |
Ionization probe assemblies
|
|
ES2560107T3
(es)
|
2009-02-12 |
2016-02-17 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
|
WO2010102058A2
(en)
|
2009-03-04 |
2010-09-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
|
JP6032724B2
(ja)
|
2009-03-12 |
2016-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
|
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
WO2010114842A1
(en)
|
2009-03-30 |
2010-10-07 |
Ibis Biosciences, Inc. |
Bioagent detection systems, devices, and methods
|
|
CN102449170A
(zh)
|
2009-04-15 |
2012-05-09 |
西北大学 |
寡核苷酸功能化的纳米颗粒的递送
|
|
EP3524275A1
(de)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
|
|
EP2424987B1
(de)
|
2009-05-01 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
|
|
NZ711583A
(en)
|
2009-05-05 |
2017-03-31 |
Arbutus Biopharma Corp |
Lipid compositions
|
|
WO2010129687A1
(en)
|
2009-05-05 |
2010-11-11 |
Alnylam Pharmaceuticals, Inc |
Methods of delivering oligonucleotides to immune cells
|
|
EP2427553A4
(de)
|
2009-05-06 |
2012-11-07 |
Opko Curna Llc |
Behandlung von lipidtransport- und stoffwechselgenbedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein lipidtransport- und stoffwechselgen
|
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
|
US20120107331A1
(en)
|
2009-05-15 |
2012-05-03 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
|
US8957037B2
(en)
|
2009-05-18 |
2015-02-17 |
Curna, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
|
CN102549158B
(zh)
|
2009-05-22 |
2017-09-26 |
库尔纳公司 |
通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
|
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
|
KR102066189B1
(ko)
|
2009-06-10 |
2020-01-14 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
CN102695797B
(zh)
|
2009-06-16 |
2018-05-25 |
库尔纳公司 |
通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
|
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
ES2583691T3
(es)
|
2009-06-26 |
2016-09-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
|
|
RU2612521C2
(ru)
|
2009-07-06 |
2017-03-09 |
Онтории, Инк. |
Новые пролекарства нуклеиновых кислот и способы их применения
|
|
WO2011008971A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
|
WO2011008972A1
(en)
|
2009-07-17 |
2011-01-20 |
Ibis Biosciences, Inc. |
Systems for bioagent identification
|
|
US9416409B2
(en)
|
2009-07-31 |
2016-08-16 |
Ibis Biosciences, Inc. |
Capture primers and capture sequence linked solid supports for molecular diagnostic tests
|
|
EP2462229B1
(de)
|
2009-08-05 |
2016-05-11 |
CuRNA, Inc. |
Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
|
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
US20120157324A1
(en)
|
2009-08-17 |
2012-06-21 |
Yale University |
Methylation biomarkers and methods of use
|
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
IQGAP에 대한 천연 안티센스 전사체의 억제에 의한 GTPase 활성화 단백질을 함유하는 IQ 모티프(IQGAP)와 관련된 질환의 치료
|
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2011041695A1
(en)
*
|
2009-10-02 |
2011-04-07 |
Ibis Biosciences, Inc. |
Determination of methylation status of polynucleotides
|
|
US9890408B2
(en)
*
|
2009-10-15 |
2018-02-13 |
Ibis Biosciences, Inc. |
Multiple displacement amplification
|
|
CN104628729B
(zh)
*
|
2009-10-16 |
2018-11-06 |
梅琳塔治疗公司 |
抗微生物化合物和其制备和使用方法
|
|
NZ599290A
(en)
|
2009-10-16 |
2014-10-31 |
Melinta Therapeutics Inc |
Antimicrobial compounds and methods of making and using the same
|
|
EA201270568A1
(ru)
*
|
2009-10-16 |
2012-11-30 |
Риб-Экс Фармасьютикалз, Инк. |
Антимикробные композиции и способы их получения и применения
|
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
|
US20110129832A1
(en)
*
|
2009-10-27 |
2011-06-02 |
Swift Biosciences, Inc. |
Polynucleotide Primers and Probes
|
|
EP2494075B1
(de)
|
2009-10-30 |
2018-04-04 |
Northwestern University |
Templatgesteuerte nanokonjugate
|
|
AU2010315867A1
(en)
|
2009-11-03 |
2012-06-21 |
University Of Virginia Patent Foundation |
Versatile, visible method for detecting polymeric analytes
|
|
CA2781469A1
(en)
|
2009-11-23 |
2011-05-26 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
|
RU2015132142A
(ru)
|
2009-11-30 |
2015-12-20 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
|
NO2513310T3
(de)
|
2009-12-16 |
2018-03-31 |
|
|
|
NO2516648T3
(de)
|
2009-12-23 |
2018-04-07 |
|
|
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
|
KR101853508B1
(ko)
|
2009-12-29 |
2018-06-20 |
큐알엔에이, 인크. |
종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료
|
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
|
JP5963680B2
(ja)
|
2010-01-06 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
|
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2524042A2
(de)
|
2010-01-12 |
2012-11-21 |
Yale University |
Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
|
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療
|
|
WO2011097407A1
(en)
|
2010-02-04 |
2011-08-11 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
|
EP2544703A4
(de)
|
2010-03-12 |
2013-09-18 |
Brigham & Womens Hospital |
Verfahren zur behandlung von gefässentzündungserkrankungen
|
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
CA2794187C
(en)
|
2010-03-24 |
2020-07-14 |
Rxi Pharmaceuticals Corporation |
Rna interference in ocular indications
|
|
KR20180044433A
(ko)
|
2010-03-24 |
2018-05-02 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 rna 간섭
|
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
|
US8916345B2
(en)
*
|
2010-03-26 |
2014-12-23 |
Integrated Dna Technologies, Inc. |
Methods for enhancing nucleic acid hybridization
|
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Cd274/pd−l1遺伝子の発現を阻害するための組成物および方法
|
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
|
US20110269194A1
(en)
|
2010-04-20 |
2011-11-03 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011139699A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
|
JP5896175B2
(ja)
|
2010-04-29 |
2016-03-30 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
トランスサイレチン発現の調節
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
|
KR101936011B1
(ko)
|
2010-05-03 |
2019-01-07 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
|
US8628914B2
(en)
|
2010-05-26 |
2014-01-14 |
Qiagen Gaithersburg, Inc. |
Quantitative helicase assay
|
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
CA2802059C
(en)
|
2010-06-07 |
2020-05-12 |
Firefly Bioworks, Inc. |
Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
|
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9638632B2
(en)
|
2010-06-11 |
2017-05-02 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
|
EP2582397A4
(de)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
|
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
|
AU2011282217B2
(en)
|
2010-07-19 |
2015-12-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
|
WO2012021554A1
(en)
|
2010-08-09 |
2012-02-16 |
Yale University |
Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
|
|
EP2896696B1
(de)
|
2010-09-07 |
2017-12-27 |
Integrated Dna Technologies, Inc. |
Modifikationen für Antisense-Verbindungen
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
|
KR101886457B1
(ko)
|
2010-10-06 |
2018-08-07 |
큐알엔에이, 인크. |
시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
|
|
EP2625292B1
(de)
|
2010-10-07 |
2018-12-05 |
The General Hospital Corporation |
Krebsbiomarker
|
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
|
WO2012061342A2
(en)
|
2010-11-01 |
2012-05-10 |
Arqule, Inc. |
Substituted benzo-imidazo-pyrido-diazepine compounds
|
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
EP2638163B1
(de)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-assoziierte nicht-kodierende rnas
|
|
EP3521451A1
(de)
|
2010-11-17 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation von alpha-synuklein-expression
|
|
ES2657590T3
(es)
|
2010-11-23 |
2018-03-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
|
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
|
WO2012097261A2
(en)
|
2011-01-14 |
2012-07-19 |
The General Hospital Corporation |
Methods targeting mir-128 for regulating cholesterol/lipid metabolism
|
|
PT2670411T
(pt)
|
2011-02-02 |
2019-06-18 |
Excaliard Pharmaceuticals Inc |
Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
|
|
CN103391777A
(zh)
|
2011-02-02 |
2013-11-13 |
普林斯顿大学理事会 |
作为病毒产生调节剂的去乙酰化酶调节剂
|
|
WO2012109157A2
(en)
|
2011-02-07 |
2012-08-16 |
The Governing Council Of The University Of Toronto |
Bioprobes and methods of use thereof
|
|
WO2012109395A1
(en)
|
2011-02-08 |
2012-08-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
|
CA3217805A1
(en)
|
2011-03-29 |
2012-10-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of tmprss6 gene
|
|
US10086043B2
(en)
|
2011-04-03 |
2018-10-02 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified RNA (MOD-RNA)
|
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
TWI678375B
(zh)
|
2011-06-09 |
2019-12-01 |
可娜公司 |
藉由抑制共濟蛋白(frataxin,fxn)之天然反股轉錄本治療fxn相關疾病
|
|
KR102232287B1
(ko)
|
2011-06-21 |
2021-03-29 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
|
|
RU2631805C2
(ru)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
|
EP4134433A1
(de)
|
2011-06-23 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
|
US9222093B2
(en)
|
2011-06-30 |
2015-12-29 |
The University Of Hong Kong |
Two-way, portable riboswitch mediated gene expression control device
|
|
BR112014001244A2
(pt)
|
2011-07-19 |
2017-02-21 |
Wave Life Sciences Pte Ltd |
métodos para a síntese de ácidos nucléicos funcionalizados
|
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
EP3205725B1
(de)
|
2011-08-11 |
2019-03-27 |
Ionis Pharmaceuticals, Inc. |
Selektive antisense-verbindungen und verwendungen davon
|
|
EP2751270B1
(de)
|
2011-08-29 |
2018-08-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-konjugat-komplexe und ihre verwendung
|
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
EP2756080B1
(de)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
|
CN104023749B
(zh)
|
2011-09-14 |
2019-12-17 |
西北大学 |
能穿过血脑屏障的纳米缀合物
|
|
WO2013040548A2
(en)
|
2011-09-17 |
2013-03-21 |
Yale University |
Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
|
|
CN104011210B
(zh)
|
2011-10-11 |
2018-05-01 |
布里格姆及妇女医院股份有限公司 |
神经退行性病症中的microRNA
|
|
LT2766393T
(lt)
|
2011-10-14 |
2018-10-10 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš htra1 ir jų naudojimo būdai
|
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
|
CA2895077A1
(en)
|
2011-12-12 |
2013-06-20 |
Beverly Packard |
In vivo delivery of oligonucleotides
|
|
US9970061B2
(en)
|
2011-12-27 |
2018-05-15 |
Ibis Biosciences, Inc. |
Bioagent detection oligonucleotides
|
|
IL321422A
(en)
|
2012-01-11 |
2025-08-01 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulation of ikbkap splicing
|
|
WO2013106737A1
(en)
|
2012-01-13 |
2013-07-18 |
Data2Bio |
Genotyping by next-generation sequencing
|
|
JP6509723B2
(ja)
|
2012-03-13 |
2019-05-08 |
スウィフト バイオサイエンシーズ, インコーポレイテッド |
核酸ポリメラーゼによる基質ポリヌクレオチドの大きさ制御されたホモポリマーテーリングのための方法および組成物
|
|
EP2825648B1
(de)
|
2012-03-15 |
2018-09-05 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
|
|
CA2907072A1
(en)
|
2012-03-16 |
2013-09-19 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of dmpk
|
|
AU2013202595B2
(en)
|
2012-03-30 |
2016-04-21 |
Biogen Ma Inc. |
Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
CA2871073A1
(en)
|
2012-04-20 |
2013-10-24 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
EP2841572B1
(de)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetische korrektur mutierter gene
|
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
|
CN104583398A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节基因表达的组合物和方法
|
|
WO2013173638A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
|
US20130330389A1
(en)
|
2012-06-08 |
2013-12-12 |
The Regents Of The University Of Michigan |
Ultrasound-triggerable agents for tissue engineering
|
|
BR112015000723A2
(pt)
|
2012-07-13 |
2017-06-27 |
Shin Nippon Biomedical Laboratories Ltd |
adjuvante de ácido nucléico quiral
|
|
ES2862073T3
(es)
|
2012-07-13 |
2021-10-06 |
Wave Life Sciences Ltd |
Grupo auxiliar asimétrico
|
|
CN112007045A
(zh)
|
2012-07-13 |
2020-12-01 |
波涛生命科学有限公司 |
手性控制
|
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
|
WO2014028739A1
(en)
|
2012-08-15 |
2014-02-20 |
Isis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified capping protocols
|
|
DK3421602T3
(da)
|
2012-09-06 |
2021-05-10 |
Univ Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
EP2906255B1
(de)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
|
US20150275208A1
(en)
|
2012-10-12 |
2015-10-01 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
CA2887702C
(en)
|
2012-10-26 |
2023-08-01 |
Geron Corporation |
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
|
AU2013337264B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
WO2014093537A1
(en)
|
2012-12-11 |
2014-06-19 |
Isis Pharmaceuticals, Inc. |
Competitive modulation of micrornas
|
|
EP3939614A1
(de)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
|
EP3778618A1
(de)
|
2013-02-04 |
2021-02-17 |
Ionis Pharmaceuticals, Inc. |
Selektive antisense-verbindungen und verwendungen davon
|
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
KR20150130430A
(ko)
|
2013-03-14 |
2015-11-23 |
아이시스 파마수티컬즈 인코포레이티드 |
타우 발현을 조절하는 조성물 및 방법
|
|
CN105283466A
(zh)
|
2013-03-14 |
2016-01-27 |
安第斯生物技术股份有限公司 |
用于检测和治疗多发性骨髓瘤的方法
|
|
WO2014153209A1
(en)
|
2013-03-14 |
2014-09-25 |
Andes Biotechnologies S.A. |
Antisense oligonucletotides for treatment of cancer stem cells
|
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
|
US9347095B2
(en)
|
2013-03-15 |
2016-05-24 |
Bio-Rad Laboratories, Inc. |
Digital assays for mutation detection
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
EP2978446B1
(de)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antikörper zur behandlung von morbus alzheimer
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いたゲノム編集の治療的使用
|
|
WO2015012916A2
(en)
|
2013-04-23 |
2015-01-29 |
Northwestern University |
Metal-ligand coordination polymer nanoparticles and methods for making
|
|
BR112015027322A8
(pt)
*
|
2013-05-01 |
2018-01-02 |
Isis Pharmaceuticals Inc |
Compostos antissenso conjugados e sua utilização
|
|
MX379208B
(es)
|
2013-05-22 |
2025-03-10 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de serpina1 y sus metodos de uso.
|
|
EP3828276A1
(de)
|
2013-05-22 |
2021-06-02 |
Alnylam Pharmaceuticals, Inc. |
Tmprss6-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
US20160113911A1
(en)
|
2013-06-06 |
2016-04-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
|
AU2014280847B2
(en)
|
2013-06-13 |
2019-07-04 |
Antisense Therapeutics Ltd |
Combination therapy
|
|
US20160122761A1
(en)
|
2013-06-21 |
2016-05-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
JP6617702B2
(ja)
|
2013-07-15 |
2019-12-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Fty720のアザサイクリック拘束アナログ
|
|
TWI772856B
(zh)
|
2013-07-19 |
2022-08-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
GB201313897D0
(en)
*
|
2013-08-02 |
2013-09-18 |
Maersk Olie & Gas |
Conformance control in enhanced oil recovery
|
|
HRP20200250T1
(hr)
|
2013-08-08 |
2020-05-29 |
The Scripps Research Institute |
Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
SG10201801956SA
(en)
|
2013-09-09 |
2018-04-27 |
Melinta Therapeutics Inc |
Antimicrobial compounds and methods of making and using the same
|
|
EP3038623A4
(de)
|
2013-09-09 |
2017-04-19 |
Melinta Therapeutics, Inc. |
Antimikrobielle verbindungen und verfahren zur herstellung und verwendung davon
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
TWI669393B
(zh)
|
2013-10-02 |
2019-08-21 |
艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
|
LT3052628T
(lt)
|
2013-10-04 |
2020-09-10 |
Alnylam Pharmaceuticals, Inc. |
Kompozicijos ir būdai alas1 geno raiškai nuslopinti
|
|
EP3055426B1
(de)
|
2013-10-09 |
2019-06-19 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
EP3967770B1
(de)
|
2013-10-21 |
2023-12-06 |
The General Hospital Corporation |
Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
|
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
|
EP3066219B1
(de)
|
2013-11-08 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur detektion von oligonukleotiden
|
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
|
EP3750997A1
(de)
|
2013-12-02 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
|
EP3076918A4
(de)
|
2013-12-03 |
2017-06-07 |
Northwestern University |
Liposomale partikel, verfahren zur herstellung davon und verwendungen davon
|
|
WO2015085183A2
(en)
|
2013-12-06 |
2015-06-11 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
|
JP6599334B2
(ja)
|
2013-12-20 |
2019-10-30 |
ザ ジェネラル ホスピタル コーポレイション |
血中循環腫瘍細胞に関する方法およびアッセイ
|
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
EP3095459A4
(de)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
|
|
EP3095460A4
(de)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
|
|
CN113278617A
(zh)
|
2014-01-16 |
2021-08-20 |
波涛生命科学有限公司 |
手性设计
|
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
EP3105331B1
(de)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
EP3119789B1
(de)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
LT3119888T
(lt)
|
2014-03-19 |
2021-10-11 |
Ionis Pharmaceuticals, Inc. |
Kompozicijos, skirtos ataksino 2 raiškos moduliavimui
|
|
SI3126499T1
(sl)
|
2014-04-01 |
2020-09-30 |
Biogen Ma Inc. |
Sestave za moduliranje izražanja SOD-1
|
|
US10513706B2
(en)
|
2014-04-09 |
2019-12-24 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
|
US9926556B2
(en)
|
2014-04-28 |
2018-03-27 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
BR122020024446B8
(pt)
|
2014-05-01 |
2022-06-28 |
Ionis Pharmaceuticals Inc |
Compostos para modulação da expressão do receptor do hormônio de crescimento
|
|
MX380866B
(es)
|
2014-05-01 |
2025-03-12 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del factor b del complemento.
|
|
EP3845547A1
(de)
|
2014-05-01 |
2021-07-07 |
Ionis Pharmaceuticals, Inc. |
Galnac3-modifizierte oligonukleotid-konjugat zur modulierung der angiopoietin-like-3-expression
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
|
CN112301031A
(zh)
|
2014-05-22 |
2021-02-02 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3148564B1
(de)
|
2014-06-02 |
2020-01-08 |
Children's Medical Center Corporation |
Verfahren und zusammensetzungen zur immunmodulation
|
|
CA2953216C
(en)
|
2014-06-04 |
2020-12-22 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
US10308940B2
(en)
|
2014-06-10 |
2019-06-04 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of Pompe disease
|
|
US9909187B2
(en)
|
2014-06-24 |
2018-03-06 |
Abbott Molecular Inc. |
Detection of single nucleotide polymorphisms in human KRAS
|
|
EP3760208B1
(de)
|
2014-06-25 |
2024-05-29 |
The General Hospital Corporation |
Targeting von humanem satellit ii (hsatii)
|
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
|
WO2016018665A1
(en)
|
2014-07-31 |
2016-02-04 |
Uab Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
|
US12264344B2
(en)
|
2014-08-19 |
2025-04-01 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
US9617541B2
(en)
|
2014-08-20 |
2017-04-11 |
Northwestern University |
Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation
|
|
AU2015308721B2
(en)
|
2014-08-29 |
2021-04-01 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
|
EP3185957B1
(de)
|
2014-08-29 |
2022-06-01 |
Alnylam Pharmaceuticals, Inc. |
Patisiran zur behandlung von transthyretin-vermittelter amyloidose
|
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
US10556020B2
(en)
|
2014-09-26 |
2020-02-11 |
University Of Massachusetts |
RNA-modulating agents
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
|
US10822369B2
(en)
|
2014-11-14 |
2020-11-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|
|
AU2015350120B2
(en)
|
2014-11-17 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
|
EP3220895B1
(de)
|
2014-11-21 |
2022-08-31 |
Northwestern University |
Sequenzspezifische zelluläre aufnahme von sphärischen nukleinsäurenanopartikelkonjugaten
|
|
AU2015360794B2
(en)
|
2014-12-08 |
2021-07-08 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
|
JP6997623B2
(ja)
|
2014-12-12 |
2022-02-04 |
エム. ウルフ、トッド |
オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法
|
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
EP3247988A4
(de)
|
2015-01-23 |
2018-12-19 |
Vanderbilt University |
Robustes interferometer und verfahren zur verwendung davon
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
EP3262173A2
(de)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
BR112017019349A2
(pt)
|
2015-03-11 |
2018-06-05 |
Melinta Therapeutics Inc |
compostos antimicrobianos e métodos de fabricação e uso dos mesmos
|
|
BR112017020750A2
(pt)
|
2015-03-27 |
2018-06-26 |
Harvard College |
células t modificadas e métodos de produção e utilização das mesmas
|
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
|
CA2981960C
(en)
|
2015-04-08 |
2023-09-19 |
The University Of Chicago |
Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
|
EP3310918B1
(de)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
JP2018524588A
(ja)
|
2015-06-26 |
2018-08-30 |
ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド |
骨髄由来サプレッサー細胞中のテトラスパニン33(Tspan33)を標的化するがん療法
|
|
IL256634B2
(en)
|
2015-06-29 |
2025-08-01 |
Caris Science Inc |
Therapeutic oligonucleotides
|
|
EP3313989B1
(de)
|
2015-06-29 |
2024-12-25 |
Ionis Pharmaceuticals, Inc. |
Modifizierte crispr-rna und modifizierte single-crispr-rna und verwendungen davon
|
|
KR20180026739A
(ko)
|
2015-07-06 |
2018-03-13 |
알엑스아이 파마슈티칼스 코포레이션 |
슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
ES2917181T3
(es)
|
2015-07-10 |
2022-07-07 |
Ionis Pharmaceuticals Inc |
Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
WO2017019918A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
|
EP3332009A1
(de)
|
2015-08-04 |
2018-06-13 |
Yeda Research and Development Co., Ltd. |
Verfahren zum screening auf riboswitches und attenuatoren
|
|
EA201890619A1
(ru)
|
2015-09-02 |
2018-09-28 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
JP7041616B2
(ja)
|
2015-09-14 |
2022-03-24 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
リポカチオン性デンドリマーおよびその使用
|
|
JP6853539B2
(ja)
|
2015-09-24 |
2021-03-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
|
|
EP3353328A4
(de)
|
2015-09-24 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
Modulatoren der kras-expression
|
|
JP2018532402A
(ja)
|
2015-09-24 |
2018-11-08 |
クリスパー セラピューティクス アーゲー |
Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
|
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
|
US10709812B2
(en)
|
2015-09-29 |
2020-07-14 |
The Regents Of The University Of Michigan |
Biodegradable hydrogel for tissue expansion
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
EP3365446A4
(de)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
Gegen lange nichtcodierende rna gerichtete kleine selbstfreisetzende nukleinsäureverbindungen
|
|
CN108513546A
(zh)
|
2015-10-28 |
2018-09-07 |
克里斯珀医疗股份公司 |
用于治疗杜氏肌营养不良症的材料和方法
|
|
ES2870141T3
(es)
|
2015-10-30 |
2021-10-26 |
Hoffmann La Roche |
Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
|
|
ES2938883T3
(es)
|
2015-11-05 |
2023-04-17 |
Los Angeles Childrens Hospital |
Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
|
|
BR112018008971A2
(pt)
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
|
|
CN113952353A
(zh)
|
2015-11-06 |
2022-01-21 |
Ionis制药公司 |
调节载脂蛋白(a)表达
|
|
PT4119569T
(pt)
|
2015-11-06 |
2024-10-23 |
Ionis Pharmaceuticals Inc |
Compostos antissentido conjugados para utilização em terapia
|
|
US11001622B2
(en)
|
2015-11-19 |
2021-05-11 |
The Brigham And Women's Hospital, Inc. |
Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
|
|
AU2016362282B2
(en)
|
2015-11-30 |
2023-03-16 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
WO2017093804A2
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
ES3041380T3
(en)
|
2015-12-07 |
2025-11-11 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
|
WO2017099579A1
(en)
|
2015-12-07 |
2017-06-15 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
|
EP3394260B1
(de)
|
2015-12-23 |
2021-02-17 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von amyothrophischer lateraler sklerose und/oder frontotemporaler demenz
|
|
EP3397288A4
(de)
|
2015-12-31 |
2019-09-11 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur reduzierung der ataxin-2-expression
|
|
EP3400300A4
(de)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur reduzierung der lrrk2-expression
|
|
EP3408649B1
(de)
|
2016-01-29 |
2023-06-14 |
Vanderbilt University |
Interferometrie mit antwortfunktion in freier lösung
|
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
|
EP3411396A1
(de)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
|
WO2017141109A1
(en)
|
2016-02-18 |
2017-08-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
|
DK3419665T3
(da)
|
2016-02-25 |
2025-01-13 |
Brigham & Womens Hospital Inc |
Behandlingsfremgangsmåder til fibrose ved målretning af SMOC2
|
|
WO2017152182A1
(en)
|
2016-03-04 |
2017-09-08 |
Rhode Island Hospital |
Targeting microrna for cancer treatment
|
|
WO2017156242A1
(en)
|
2016-03-09 |
2017-09-14 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting pmp22 expression
|
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
|
US10961271B2
(en)
|
2016-03-16 |
2021-03-30 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
US11083799B2
(en)
|
2016-03-16 |
2021-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
|
WO2017161357A1
(en)
|
2016-03-18 |
2017-09-21 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
AU2017248637A1
(en)
|
2016-04-13 |
2018-09-27 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing C9ORF72 expression
|
|
MX2018012729A
(es)
|
2016-04-18 |
2019-07-04 |
Crispr Therapeutics Ag |
Materiales y metodos para el tratamiento de hemoglobinopatias.
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
US11098047B2
(en)
|
2016-05-06 |
2021-08-24 |
BioVersys AG |
Antimicrobials and methods of making and using same
|
|
CA3021994A1
(en)
|
2016-05-06 |
2017-11-09 |
Brett P. Monia |
Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
|
|
CN109414408B
(zh)
|
2016-05-16 |
2022-03-29 |
得克萨斯州大学系统董事会 |
阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
|
|
EP3464597B1
(de)
|
2016-05-25 |
2022-08-03 |
Caris Science, Inc. |
Selectionsverfahren von oligonukleotidsonden und verwendungen davon
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
US11708614B2
(en)
|
2016-06-15 |
2023-07-25 |
Streck Llc |
Assays and methods for determining microbial resistance
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
ES2929047T3
(es)
|
2016-06-24 |
2022-11-24 |
Scripps Research Inst |
Transportador de nucleósido trifosfato novedoso y usos del mismo
|
|
US11174469B2
(en)
|
2016-06-29 |
2021-11-16 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
|
|
AU2017290614C1
(en)
|
2016-06-29 |
2024-01-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
EP3481857A1
(de)
|
2016-07-06 |
2019-05-15 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schmerbedingten erkrankungen
|
|
AU2017292169B2
(en)
|
2016-07-06 |
2021-12-23 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
PE20190513A1
(es)
|
2016-07-15 |
2019-04-10 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la modulacion de smn2
|
|
EP4275747A3
(de)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutische anwendungen von cpf1-basierter genomeditierung
|
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
|
WO2018035380A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
|
CN109661233A
(zh)
|
2016-10-06 |
2019-04-19 |
Ionis 制药公司 |
缀合低聚化合物的方法
|
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018089582A1
(en)
|
2016-11-10 |
2018-05-17 |
San Diego State University Research Foundation |
Compounds for fluorescence sensing of duplex formation
|
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
JP7206214B2
(ja)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
|
TWI790217B
(zh)
|
2016-12-16 |
2023-01-21 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法
|
|
RU2019126483A
(ru)
|
2017-01-23 |
2021-02-24 |
Ридженерон Фармасьютикалз, Инк. |
Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
|
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
|
US20200040061A1
(en)
|
2017-02-22 |
2020-02-06 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
US11559588B2
(en)
|
2017-02-22 |
2023-01-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
|
|
US20200216857A1
(en)
|
2017-02-22 |
2020-07-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
JP2020508056A
(ja)
|
2017-02-22 |
2020-03-19 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
遺伝子編集のための組成物および方法
|
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US20180284123A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
|
|
IL269970B
(en)
|
2017-04-14 |
2022-09-01 |
Tallac Therapeutics Inc |
Polynucleotides that modulate the immune system, their antibody binding, and methods of using them
|
|
CN118384268A
(zh)
|
2017-04-18 |
2024-07-26 |
阿尔尼拉姆医药品有限公司 |
具有乙肝病毒(hbv)感染的受试者的治疗方法
|
|
KR102778110B1
(ko)
|
2017-04-20 |
2025-03-10 |
신테나 아게 |
트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도
|
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
|
JP7356354B2
(ja)
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
|
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|
|
JP2020530442A
(ja)
|
2017-07-10 |
2020-10-22 |
ジェンザイム・コーポレーション |
血友病を有する対象の出血事象を処置するための方法および組成物
|
|
CN111051512A
(zh)
|
2017-07-11 |
2020-04-21 |
辛索克斯公司 |
非天然核苷酸的掺入及其方法
|
|
MA49716A
(fr)
|
2017-07-11 |
2021-04-07 |
Scripps Research Inst |
Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
|
|
KR20200028997A
(ko)
|
2017-07-13 |
2020-03-17 |
노오쓰웨스턴 유니버시티 |
올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
|
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
|
SG11202000939PA
(en)
|
2017-08-03 |
2020-02-27 |
Synthorx Inc |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
WO2019055460A1
(en)
|
2017-09-13 |
2019-03-21 |
The Children's Medical Center Corporation |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
|
|
KR20250046363A
(ko)
|
2017-09-19 |
2025-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
|
WO2019081982A1
(en)
|
2017-10-26 |
2019-05-02 |
Crispr Therapeutics Ag |
SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
EP3707155A2
(de)
|
2017-11-09 |
2020-09-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas-systeme für die behandlung von dmd
|
|
EP3710587A1
(de)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
US10662425B2
(en)
|
2017-11-21 |
2020-05-26 |
Crispr Therapeutics Ag |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
MA51107A
(fr)
|
2017-12-05 |
2020-10-14 |
Vertex Pharma |
Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées
|
|
CN111801417B
(zh)
|
2017-12-14 |
2024-10-29 |
克里斯珀医疗股份公司 |
新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途
|
|
US11725208B2
(en)
|
2017-12-14 |
2023-08-15 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
CN111727252A
(zh)
|
2017-12-18 |
2020-09-29 |
阿尔尼拉姆医药品有限公司 |
高速泳动族盒-1(HMGB1)iRNA组合物及其使用方法
|
|
EP3728595A1
(de)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
|
|
JP7402163B2
(ja)
|
2017-12-21 |
2023-12-20 |
クリスパー セラピューティクス アーゲー |
2a型アッシャー症候群の処置のための材料および方法
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
IL319501A
(en)
|
2017-12-29 |
2025-05-01 |
Scripps Research Inst |
Unnatural nucleotide compounds and methods of using them
|
|
US12178855B2
(en)
|
2018-01-10 |
2024-12-31 |
Translate Bio Ma, Inc. |
Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
|
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
|
CN120310791A
(zh)
|
2018-01-12 |
2025-07-15 |
百时美施贵宝公司 |
靶向α-突触核蛋白的反义寡核苷酸及其用途
|
|
SG11202006528XA
(en)
|
2018-01-12 |
2020-08-28 |
Bristol Myers Squibb Co |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
JP2021511072A
(ja)
|
2018-01-15 |
2021-05-06 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. |
Dnm2発現のモジュレーター
|
|
US12319667B2
(en)
|
2018-01-19 |
2025-06-03 |
Synthena Ag |
Tricyclo-DNA nucleoside precursors and processes for preparing the same
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
EP3749767A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
|
WO2019150203A1
(en)
|
2018-02-05 |
2019-08-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
WO2019161310A1
(en)
|
2018-02-16 |
2019-08-22 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
|
AR114445A1
(es)
|
2018-02-26 |
2020-09-09 |
Synthorx Inc |
Conjugados de il-15, y sus usos
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
|
EP3768834B1
(de)
|
2018-03-19 |
2025-08-13 |
CRISPR Therapeutics AG |
Neuartige rna-programmierbare endonukleasesysteme und deren verwendung in der genombearbeitung und in anderen anwendungen
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
CN112513297B
(zh)
|
2018-03-28 |
2024-10-22 |
得克萨斯州大学系统董事会 |
鉴定从外排体分离的dna中的表观遗传改变
|
|
WO2019186514A2
(en)
|
2018-03-30 |
2019-10-03 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
|
WO2019195738A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
|
CA3091490A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
|
WO2019213016A1
(en)
|
2018-04-30 |
2019-11-07 |
The Children's Hospital Of Philadelphia |
Methods of improving anemias by combining agents
|
|
WO2019213571A1
(en)
|
2018-05-03 |
2019-11-07 |
The Trustees Of Wheaton College |
Improved membranes for nanopore sensing applications
|
|
MY204000A
(en)
|
2018-05-09 |
2024-07-31 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
|
MX2020011911A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir de la expresion de atxn3.
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
JP7557378B2
(ja)
|
2018-06-14 |
2024-09-27 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Stmn2発現を増加させるための化合物及び方法
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
EP3823725A4
(de)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
Verfahren zur sicheren reduzierung von thrombopoietin
|
|
TWI843738B
(zh)
|
2018-07-25 |
2024-06-01 |
美商Ionis製藥公司 |
用於減少atxn2表現之化合物及方法
|
|
BR112021001613A2
(pt)
|
2018-08-13 |
2021-05-04 |
Alnylam Pharmaceuticals, Inc. |
agentes de ácido ribonucleico de fita dupla, célula, composições farmacêuticas, métodos de inibição da expressão gênica, de inibição da replicação e de tratar um sujeito, métodos para reduzir o nível de um antígeno e para reduzir a carga viral e uso de um agente de dsrna
|
|
EP3837367A1
(de)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
|
EA202190581A1
(ru)
|
2018-08-20 |
2021-07-13 |
Рогкон, Инк. |
Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
|
|
WO2020047229A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
|
AU2019339509A1
(en)
|
2018-09-14 |
2021-05-13 |
Northwestern University |
Programming protein polymerization with DNA
|
|
EP3853364A1
(de)
|
2018-09-18 |
2021-07-28 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
CA3292164A1
(en)
|
2018-09-25 |
2025-11-29 |
Co Diagnostics Inc |
Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
|
|
BR112021007403A2
(pt)
|
2018-10-17 |
2021-12-07 |
Bayer Healthcare Llc |
Composições e métodos para entrega de transgenes
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
AU2019376076B9
(en)
|
2018-11-08 |
2025-06-19 |
Synthorx, Inc. |
Interleukin 10 conjugates and uses thereof
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
SG11202104666SA
(en)
|
2018-11-15 |
2021-06-29 |
Ionis Pharmaceuticals Inc |
Modulators of irf5 expression
|
|
BR112021007476A2
(pt)
|
2018-11-21 |
2021-11-03 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir a expressão de príon
|
|
CN113710799B
(zh)
|
2018-11-28 |
2024-11-12 |
克里斯珀医疗股份公司 |
用于在LNP中使用的编码CAS9的优化mRNA
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
|
AU2019406186A1
(en)
|
2018-12-20 |
2021-07-15 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of KCNT1 related disorders
|
|
HRP20231338T1
(hr)
|
2018-12-20 |
2024-02-16 |
Vir Biotechnology, Inc. |
Kombinirana terapija hbv
|
|
AU2019406214A1
(en)
|
2018-12-21 |
2021-08-05 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
|
MX2021007503A
(es)
|
2018-12-21 |
2021-08-05 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de hsd17b13.
|
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
|
CN113557023A
(zh)
|
2019-01-16 |
2021-10-26 |
建新公司 |
Serpinc1 iRNA组合物及其使用方法
|
|
WO2020160453A1
(en)
|
2019-01-31 |
2020-08-06 |
Ionis Pharmaceuticals, Inc. |
Modulators of yap1 expression
|
|
AU2020218203A1
(en)
|
2019-02-06 |
2021-08-26 |
Synthorx, Inc. |
IL-2 conjugates and methods of use thereof
|
|
AU2020221340A1
(en)
|
2019-02-15 |
2021-09-16 |
Bayer Healthcare Llc |
Gene editing for hemophilia A with improved Factor VIII expression
|
|
MY208565A
(en)
|
2019-02-27 |
2025-05-15 |
Ionis Pharmaceuticals Inc |
Modulators of malat1 expression
|
|
US20220175956A1
(en)
|
2019-03-06 |
2022-06-09 |
Northwestern University |
Hairpin-like oligonucleotide-conjugated spherical nucleic acid
|
|
CN113924127A
(zh)
|
2019-03-11 |
2022-01-11 |
奥克斯纳健康系统公司 |
在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络
|
|
WO2020186059A2
(en)
|
2019-03-12 |
2020-09-17 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
|
CR20210538A
(es)
|
2019-03-29 |
2021-12-06 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular ube3a-ats
|
|
PH12021552870A1
(en)
|
2019-05-13 |
2022-03-21 |
Vir Biotechnology Inc |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
ES3033104T3
(en)
|
2019-05-28 |
2025-07-30 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fus expression
|
|
US20250270657A1
(en)
|
2019-05-31 |
2025-08-28 |
Streck, Inc. |
Detection of Antibiotic Resistance Genes
|
|
EP3983543A4
(de)
|
2019-06-14 |
2023-05-03 |
The Scripps Research Institute |
Reagenzien und verfahren zur replikation, transkription und translation in halbsynthetischen organismen
|
|
ES3048358T3
(en)
|
2019-07-26 |
2025-12-10 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating gfap
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4007812A1
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
|
|
EP4013870A1
(de)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
|
|
JP7679355B2
(ja)
|
2019-08-15 |
2025-05-19 |
シンソークス, インコーポレイテッド |
Il-2コンジュゲートを用いる免疫腫瘍学併用療
|
|
KR20220062517A
(ko)
|
2019-08-15 |
2022-05-17 |
아이오니스 파마수티컬즈, 인코포레이티드 |
결합 변형된 올리고머 화합물 및 이의 용도
|
|
WO2021041206A1
(en)
|
2019-08-23 |
2021-03-04 |
Synthorx, Inc. |
Il-15 conjugates and uses thereof
|
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
TW202124385A
(zh)
|
2019-09-10 |
2021-07-01 |
美商欣爍克斯公司 |
治療自體免疫疾病之il-2接合物及使用方法
|
|
US12319711B2
(en)
|
2019-09-20 |
2025-06-03 |
Northwestern University |
Spherical nucleic acids with tailored and active protein coronae
|
|
EP4038189A1
(de)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
|
|
JP7757277B2
(ja)
|
2019-10-14 |
2025-10-21 |
アストラゼネカ・アクチエボラーグ |
Pnpla3発現のモジュレーター
|
|
EP4045652A1
(de)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
|
|
EP4048793A1
(de)
|
2019-10-22 |
2022-08-31 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
|
US12378560B2
(en)
|
2019-10-29 |
2025-08-05 |
Northwestern University |
Sequence multiplicity within spherical nucleic acids
|
|
US20240168004A1
(en)
|
2019-10-31 |
2024-05-23 |
The Trustees Of Wheaton College |
Design and characterization of multilayered structures for support of lipid bilayers
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CA3155921A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
CA3156405A1
(en)
|
2019-11-04 |
2021-05-14 |
Synthorx, Inc. |
Interleukin 10 conjugates and uses thereof
|
|
CN114981431A
(zh)
|
2019-11-13 |
2022-08-30 |
阿尔尼拉姆医药品有限公司 |
用于治疗血管紧张素原(agt)相关病症的方法和组合物
|
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
|
CN115335521A
(zh)
|
2019-11-27 |
2022-11-11 |
克里斯珀医疗股份公司 |
合成rna分子的方法
|
|
BR112022011417A2
(pt)
|
2019-12-13 |
2022-08-30 |
Alnylam Pharmaceuticals Inc |
Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
|
US20230054569A1
(en)
|
2019-12-18 |
2023-02-23 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
WO2021154705A1
(en)
|
2020-01-27 |
2021-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
CA3170377A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
|
JP7735288B2
(ja)
|
2020-02-18 |
2025-09-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法
|
|
US11920136B2
(en)
|
2020-02-28 |
2024-03-05 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
|
JP7446443B2
(ja)
|
2020-02-28 |
2024-03-08 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Smn2を調節するための化合物及び方法
|
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
|
EP4114948A1
(de)
|
2020-03-06 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
コロナウイルスiRNA組成物およびその使用方法
|
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
|
US20230295622A1
(en)
|
2020-04-06 |
2023-09-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
US20230159933A1
(en)
|
2020-04-07 |
2023-05-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
|
BR112022021462A2
(pt)
|
2020-04-21 |
2023-01-17 |
Flagship Pioneering Inc |
Moléculas bifuncionais e métodos de sua utilização
|
|
EP4143319A1
(de)
|
2020-04-27 |
2023-03-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
|
|
CN116096381A
(zh)
|
2020-04-30 |
2023-05-09 |
阿尔尼拉姆医药品有限公司 |
补体因子B(CFB)iRNA组合物及其使用方法
|
|
IL297435A
(en)
|
2020-05-01 |
2022-12-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating atxn1
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
|
EP4150087A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
|
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
|
WO2021257782A1
(en)
|
2020-06-18 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
IL299201A
(en)
|
2020-06-24 |
2023-02-01 |
Vir Biotechnology Inc |
Transgenic hepatitis B virus neutralizing antibodies and their uses
|
|
KR20230027235A
(ko)
|
2020-06-25 |
2023-02-27 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
|
|
JP2023532518A
(ja)
|
2020-06-29 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Plp1を調節するための化合物及び方法
|
|
BR112023001624A2
(pt)
|
2020-07-28 |
2023-02-23 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir a expressão de app
|
|
JP2023536994A
(ja)
|
2020-08-07 |
2023-08-30 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Scn2aを調節する化合物および方法
|
|
US12329828B2
(en)
|
2020-09-16 |
2025-06-17 |
San Diego State University (Sdsu) Foundation |
Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy
|
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
US20230392134A1
(en)
|
2020-09-30 |
2023-12-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
JP2023546009A
(ja)
|
2020-10-09 |
2023-11-01 |
シンソークス, インコーポレイテッド |
Il-2コンジュゲートおよびペムブロリズマブを用いる免疫腫瘍学併用療法
|
|
CA3194880A1
(en)
|
2020-10-09 |
2022-04-14 |
Carolina E. CAFFARO |
Immuno oncology therapies with il-2 conjugates
|
|
CN116615235A
(zh)
|
2020-10-09 |
2023-08-18 |
得克萨斯州大学系统董事会 |
融合前稳定的hmpv f蛋白
|
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
CN116761885A
(zh)
|
2020-10-23 |
2023-09-15 |
斯克利普斯研究所 |
包含非天然核苷酸的多核苷酸的逆转录
|
|
EP4244355A1
(de)
|
2020-11-13 |
2023-09-20 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor-v (f5)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
|
WO2022106695A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
CA3205040A1
(en)
|
2020-12-18 |
2022-06-23 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor xii
|
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
TW202245843A
(zh)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
|
|
EP4291243A1
(de)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
|
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
|
AU2022226098A1
(en)
|
2021-02-26 |
2023-08-24 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP2024508896A
(ja)
|
2021-03-04 |
2024-02-28 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンジオポエチン様3(ANGPTL3)iRNA組成物およびその使用方法
|
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
TW202305134A
(zh)
|
2021-03-29 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓蛋白(HTT)iRNA劑組成物及其使用方法
|
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2022214632A1
(en)
|
2021-04-07 |
2022-10-13 |
Neoplants Sas |
Compositions and methods for indoor air remediation
|
|
AU2022262422A1
(en)
|
2021-04-22 |
2023-11-02 |
The Board Of Regents Of The University Of Texas System |
All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
|
|
IL307926A
(en)
|
2021-04-26 |
2023-12-01 |
Alnylam Pharmaceuticals Inc |
Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
|
|
EP4330396A1
(de)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2022235537A1
(en)
|
2021-05-03 |
2022-11-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
TW202313679A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
|
|
TW202308663A
(zh)
|
2021-06-04 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
人類染色體9開讀框72(C9ORF72)iRNA劑組成物及其使用方法
|
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
|
BR112023023768A2
(pt)
|
2021-06-11 |
2024-02-27 |
Bayer Ag |
Sistemas de endonucleases programáveis por rna tipo v
|
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
|
MX2023015230A
(es)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de ifnar1.
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
MX2023015489A
(es)
|
2021-06-30 |
2024-01-19 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt).
|
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
|
TW202325312A
(zh)
|
2021-07-23 |
2023-07-01 |
美商艾拉倫製藥股份有限公司 |
β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法
|
|
EP4377458A1
(de)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
IL310295A
(en)
|
2021-08-04 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
|
JP2024534766A
(ja)
|
2021-08-13 |
2024-09-26 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
第XII因子(F12)iRNA組成物およびその使用方法
|
|
EP4395790A2
(de)
|
2021-08-31 |
2024-07-10 |
Alnylam Pharmaceuticals, Inc. |
Zelltodinduzierende dffa-ähnliche effektor-b (cideb)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
|
EP4401742A2
(de)
|
2021-09-17 |
2024-07-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen und verfahren zur dämpfung der komplementkomponente 3 (c3)
|
|
CN118159654A
(zh)
|
2021-09-20 |
2024-06-07 |
阿尔尼拉姆医药品有限公司 |
抑制素亚基βE(INHBE)调节剂组合物及其使用方法
|
|
PE20241065A1
(es)
|
2021-09-30 |
2024-05-13 |
Akouos Inc |
Composiciones y metodos para el tratamiento de la perdida de audicion asociada a kcnq4
|
|
CA3233755A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
EP4423272A2
(de)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
|
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
US20250019702A1
(en)
|
2021-11-10 |
2025-01-16 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
EP4430187A2
(de)
|
2021-11-10 |
2024-09-18 |
University of Rochester |
Antisense oligonukleotide zur änderung der proteinexpression
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
CA3243006A1
(en)
|
2021-12-21 |
2025-02-27 |
Alia Therapeutics Srl |
TYPE II CAS PROTEINS AND THEIR APPLICATIONS
|
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
|
EP4453191A1
(de)
|
2021-12-23 |
2024-10-30 |
Bayer Aktiengesellschaft |
Neuartige programmierbare endonukleasesysteme für kleine v-rna
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
EP4486890A1
(de)
|
2022-03-01 |
2025-01-08 |
CRISPR Therapeutics AG |
Verfahren und zusammensetzungen zur behandlung von angiopoietin-like 3 (angptl3)-bedingten erkrankungen
|
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
|
IL316824A
(en)
|
2022-06-10 |
2025-01-01 |
Bayer Ag |
Novel small, programmable endonuclease systems for type V RNA
|
|
CN120077130A
(zh)
|
2022-08-18 |
2025-05-30 |
阿尔尼拉姆医药品有限公司 |
通用非靶向sirna组合物及其使用方法
|
|
EP4581143A1
(de)
|
2022-08-29 |
2025-07-09 |
University of Rochester |
Anti-fibrotische therapeutika auf der basis von antisense-oligonukleotiden
|
|
MA71735A
(fr)
|
2022-09-15 |
2025-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|
|
EP4587564A2
(de)
|
2022-09-16 |
2025-07-23 |
Alia Therapeutics Srl |
Enqp-typ-ii-cas-proteine und anwendungen davon
|
|
AU2023347222A1
(en)
|
2022-09-23 |
2025-03-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing mecp2 expression
|
|
EP4619535A1
(de)
|
2022-11-16 |
2025-09-24 |
Alia Therapeutics Srl |
Typ-ii-cas-proteine und anwendungen davon
|
|
AU2023398007A1
(en)
|
2022-12-13 |
2025-06-19 |
Bayer Aktiengesellschaft |
Engineered type v rna programmable endonucleases and their uses
|
|
WO2024136899A1
(en)
|
2022-12-21 |
2024-06-27 |
Synthorx, Inc. |
Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
|
|
IL321992A
(en)
|
2023-01-09 |
2025-09-01 |
Univ Texas |
Human parainfluenza virus 3f proteins stabilized before transfusion
|
|
EP4649147A2
(de)
|
2023-01-11 |
2025-11-19 |
Alia Therapeutics Srl |
Typ-ii-cas-proteine und anwendungen davon
|
|
WO2024168010A2
(en)
|
2023-02-09 |
2024-08-15 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
|
EP4665865A1
(de)
|
2023-02-17 |
2025-12-24 |
Anjarium Biosciences AG |
Verfahren zur herstellung von dna-molekülen und zusammensetzungen und verwendungen davon
|
|
TW202444349A
(zh)
|
2023-03-20 |
2024-11-16 |
美商欣爍克斯公司 |
使用il-2綴合物之癌症療法
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
WO2024196965A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
AU2024244071A1
(en)
|
2023-04-06 |
2025-10-30 |
Shanghai Argo Biopharmaceutical Co., Ltd. |
Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
|
|
TW202448484A
(zh)
|
2023-04-20 |
2024-12-16 |
美商雅迪克斯製藥公司 |
Mapt調節組合物及其使用方法
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
TW202502385A
(zh)
|
2023-05-12 |
2025-01-16 |
美商雅迪克斯製藥公司 |
Nmda配位體結合之化合物及其用途
|
|
WO2024243062A1
(en)
|
2023-05-19 |
2024-11-28 |
Streck Llc |
Detection of antibiotic resistance genes
|
|
AU2024279767A1
(en)
|
2023-05-26 |
2025-12-04 |
Adarx Pharmaceuticals, Inc. |
Sod1-modulating compositions and methods of use thereof
|
|
WO2024263694A1
(en)
|
2023-06-20 |
2024-12-26 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
WO2025003344A1
(en)
|
2023-06-28 |
2025-01-02 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015335A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025024493A1
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025024486A2
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
TW202526017A
(zh)
|
2023-09-14 |
2025-07-01 |
美商Ionis製藥公司 |
用於減少apociii表現的化合物及方法
|
|
US20250215044A1
(en)
|
2023-09-21 |
2025-07-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and Methods for Inhibiting LPA
|
|
GB202314724D0
(en)
|
2023-09-26 |
2023-11-08 |
Astrazeneca Ab |
compounds and methods for reducing psd3 expression
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
TW202521691A
(zh)
|
2023-10-06 |
2025-06-01 |
美商藍岩醫療公司 |
經工程化之v型rna可程式核酸內切酶及其用途
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025158385A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Pegylated il-2 for suppressing adaptive immune response to gene therapy
|
|
WO2025165891A1
(en)
|
2024-01-29 |
2025-08-07 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
US20250263702A1
(en)
|
2024-02-19 |
2025-08-21 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting cideb and related methods
|
|
WO2025199231A2
(en)
|
2024-03-20 |
2025-09-25 |
Vertex Pharmaceuticals Incorporated |
Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
|
|
WO2025207517A2
(en)
|
2024-03-25 |
2025-10-02 |
Synthorx, Inc. |
Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
|
|
GB202404290D0
(en)
|
2024-03-26 |
2024-05-08 |
Senisca Ltd |
Novel oligoncleotides
|
|
WO2025210147A1
(en)
|
2024-04-04 |
2025-10-09 |
Alia Therapeutics Srl |
Type v cas proteins and applications thereof
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025259743A1
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dual conjugate compounds for extrahepatic delivery
|
|
WO2025259747A2
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
|